CA2160607A1 - Assay method for analyte in living body - Google Patents
Assay method for analyte in living bodyInfo
- Publication number
- CA2160607A1 CA2160607A1 CA002160607A CA2160607A CA2160607A1 CA 2160607 A1 CA2160607 A1 CA 2160607A1 CA 002160607 A CA002160607 A CA 002160607A CA 2160607 A CA2160607 A CA 2160607A CA 2160607 A1 CA2160607 A1 CA 2160607A1
- Authority
- CA
- Canada
- Prior art keywords
- particles
- substance
- body fluid
- magnetic
- magnetic particles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
- G01N33/54333—Modification of conditions of immunological binding reaction, e.g. use of more than one type of particle, use of chemical agents to improve binding, choice of incubation time or application of magnetic field during binding reaction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
- G01N33/5434—Magnetic particles using magnetic particle immunoreagent carriers which constitute new materials per se
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/551—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
- G01N33/553—Metal or metal coated
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2446/00—Magnetic particle immunoreagent carriers
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
A process for assaying a biological substance is provided. In the assay, a reagent comprising magnetic particles having loaded thereon a substance that binds to the target substance is utilized; non-magnetic colored particles; and magnetic particles having loaded thereon a substance that binds to an assay interfering substance is utilized. The assay is carried out by mixing the reagent with the body fluid; magnetically removing the magnetic particles and the substances that were bound to the magnetic particles; and measuring the amount of the remaining non-magnetic colored particles. Even when the body fluid specimen is measured with no pretreatment, measurements of high sensitivity and high reliability can be obtained in a short period without being interfered with the assay interfering substances in the body fluid.
Description
216~607 TITLE OF TE~E I~VENTION
Process for Assaying Biological Substance FIELD OF TUE INVENTION
This invention is an i~ r ~1V~LL~t in the process _or assaying a biological substance by means of an immunoreaction llt;1;7;n~ magnetic particles and non-magnetic particles. More particularly, this invention relates to a process _or assaying a target biological substance that enables use of a body fluid for the specimen, and that is capable of obtaining measurements o~
high sensitivity and high reliability in a quite short period without being ;nflll~n~ by the substances in the body fluid that interferes with the assay.
BACKGROUND OF THE INVENTION
Use o~ magnetic particles in an ;~mllnn~C say comprising the step of reacting an antigen with an antibody is disclosed in USP 4177253.
A method for assaying an antigen or an antibody comprising the steps of loading an antibody or an antigen on insoluble carrier particles, and allowing the thus loaded antibody or antigen to react with an antigen or an antibody or a mixture thereof in a li~uid medium to measure the increase/decrease of the reaction p~oduct is disclosed, for example, in ~Japanese Patent Application Laid-Open No.
1-193647. In this method, the reaction is effected by using magnetic and non-magnetic particles for the carrier ~ 2160607 particles; a magnetic field is applied to remove the magnetic particles ;nrlll~;nrJ the magnetic particles that failed to react from the reaction mixture; and the ~ ~ ; n; n~ non-magnetic particles are detected to thereby r~ alitatively or (auantitatively determine the antigen or the antibody in the li~uid medium.
In the methods as described above, a reliable, accurate measurement could be e~fected only when the specimen used for the assay is a biological substance from which the substances that interfere with the assay had been remove~ .
As a matter of fact, assay at a high sensitivity could be carried out only after separating the serum sillce erythrocytes, leukocytes, platelets, hemoglobin, bilirubin, lipoproteins and the like in the whole blood interfered with the assay. Such situation is undesirable since there is a need for a highly reliable accelerated assay of a biological substance at a high sensitivity that reS~uires no pretreatment such as serum separation of the specimen used for the assay of the biological substance. A pretreatment such as serum separation for the purpose of removing the assay interfering substance should make an accelerated assay difficult to be carried out.
In view of such situation, an object of the present invention is to obviate the above-described problems of the prior art and develop a highly reliable process f or qualitatively or r,Luantitatively determining a biological substance that exhibits a high sensitivity.
216060~
SUMM~RY OF THE INVENTION
According to the present invention, there is provided a process for assaying a biological substance characterized in that said process comprises the steps (1) to (4) carried out in this order:
(1) the step of mixing a body fluid with particles (a), (b) and (c):
(a) magnetic particles having loaded thereon a substance that binds to an assay interfering substance in the body fluid through an immunoreaction;
(b) magnetic particles having loaded thereon a substance that binds to the target substance in the body fluid through an immunoreaction; and (c) non-magnetic colored particles having loaded thereon a substance that binds to the target substances in the body f luid through an i~nmunoreaction;
Process for Assaying Biological Substance FIELD OF TUE INVENTION
This invention is an i~ r ~1V~LL~t in the process _or assaying a biological substance by means of an immunoreaction llt;1;7;n~ magnetic particles and non-magnetic particles. More particularly, this invention relates to a process _or assaying a target biological substance that enables use of a body fluid for the specimen, and that is capable of obtaining measurements o~
high sensitivity and high reliability in a quite short period without being ;nflll~n~ by the substances in the body fluid that interferes with the assay.
BACKGROUND OF THE INVENTION
Use o~ magnetic particles in an ;~mllnn~C say comprising the step of reacting an antigen with an antibody is disclosed in USP 4177253.
A method for assaying an antigen or an antibody comprising the steps of loading an antibody or an antigen on insoluble carrier particles, and allowing the thus loaded antibody or antigen to react with an antigen or an antibody or a mixture thereof in a li~uid medium to measure the increase/decrease of the reaction p~oduct is disclosed, for example, in ~Japanese Patent Application Laid-Open No.
1-193647. In this method, the reaction is effected by using magnetic and non-magnetic particles for the carrier ~ 2160607 particles; a magnetic field is applied to remove the magnetic particles ;nrlll~;nrJ the magnetic particles that failed to react from the reaction mixture; and the ~ ~ ; n; n~ non-magnetic particles are detected to thereby r~ alitatively or (auantitatively determine the antigen or the antibody in the li~uid medium.
In the methods as described above, a reliable, accurate measurement could be e~fected only when the specimen used for the assay is a biological substance from which the substances that interfere with the assay had been remove~ .
As a matter of fact, assay at a high sensitivity could be carried out only after separating the serum sillce erythrocytes, leukocytes, platelets, hemoglobin, bilirubin, lipoproteins and the like in the whole blood interfered with the assay. Such situation is undesirable since there is a need for a highly reliable accelerated assay of a biological substance at a high sensitivity that reS~uires no pretreatment such as serum separation of the specimen used for the assay of the biological substance. A pretreatment such as serum separation for the purpose of removing the assay interfering substance should make an accelerated assay difficult to be carried out.
In view of such situation, an object of the present invention is to obviate the above-described problems of the prior art and develop a highly reliable process f or qualitatively or r,Luantitatively determining a biological substance that exhibits a high sensitivity.
216060~
SUMM~RY OF THE INVENTION
According to the present invention, there is provided a process for assaying a biological substance characterized in that said process comprises the steps (1) to (4) carried out in this order:
(1) the step of mixing a body fluid with particles (a), (b) and (c):
(a) magnetic particles having loaded thereon a substance that binds to an assay interfering substance in the body fluid through an immunoreaction;
(b) magnetic particles having loaded thereon a substance that binds to the target substance in the body fluid through an immunoreaction; and (c) non-magnetic colored particles having loaded thereon a substance that binds to the target substances in the body f luid through an i~nmunoreaction;
(2) the step of applying magnetic field to the mixture;
(3) the step of removing the complexes formed by the immunoreaction of the magnetic particles and the magnetic particles that failed to react by means of magnetism; and (4) the step of determining the amount of the remaining colored particles by measuring their absorption at a wave length of 350 nm or longer to thereby qualify or quantify the target substance in the body fluid without being influenced by the interfering substances in the body f luid .
216~607 In the process of the invention, the magnetic particles may preferably comprise at least one polymer selected from polystyrenes or (meth)acrylates, and have a coating layer of an iron oxide ferrite on its surface. The magnetic particles may have a diameter of from 0 1 to 5 llm, and preferably, 0 . 2 to 3 llm.
In addition, it is preferable that the body fluid is whole blood and the assay interfering substance is erythrocyte; the colored particles are colored particles of one or more types having a diameter of from 0 1 to 5 llm and having at least one color selected from white, black, red, blue, yellow and a color formed by mixing such colors; and the wave length used for measuring the absorbance is in the range of from 350 to 1000 nm.
BRIEF DESCRIPTION OF THE DRAWINGS
[FIG. 1] This figure is a schematic view for explaining the process of the invention [FIG. 2] This figure i5 a schematic view showing an example of the calibration curve used for the present invention n~Tr,r n DESCRIPTION OF THE lNVl ;N'l'lON
The target substance to be assayed by the process o~ `
the present invention is a biological substance found in human or an animal, and the specimen to be evaluated is a body fluid such as blood or urine rf~nt;~;n;nS such a subs tance A body fluid may contain biological substances such as erythrocytes, hemoglobin, bilirubin, and the like as well as drugs such as phenobarbital, phenytoin, digoxin, imipramine, theophylline, penicillin, and the like, and such a subs tance in the specimen to be determined should interfere with the assay to adversely affect the sensitivity and the accuracy of the assay.
The biological substance to be assayed in the present invention is a biological substance that is a particular antigen or antibody present in the body fluid to be assayed. Exemplary such biological substances are as described below.
Antigens: IgG, IgA, IgM, IgE, albumin, HCG, AFP, cardiolipin antigen, blood group substances, concanavalin A, DNT, prostaglandin, CRP, HBs, human growth hormone, steroid hormone, CEA, IgD, ~p(a), Apo-AI, Apo-AII, Apo-CII, Apo-CIII, Apo-B, Apo-E, hemoglobin, etc.
Antibodies: anti-albumin antibodies such as anti-albumin antibody, anti-AFP antibody, etc.; anti-globulin antibodies such as anti-HCG antibody, anti-IgG antibody, anti-IgA antibody, anti-IgM antibody, anti-IgE antibody, anti-IgD antibody, anti-CRP antibody, etc.; anti-hormone antibodies such as anti-human growth horIrlone antibody, anti-steroid antibody, etc.; anti-DNT antibody, anti-prostaglandin antibody, anti-human coagulation factor antibody, anti-HBs antibody, etc.
- In the process of the present invention, particles (a), (b) and (c~ as described below are employed.
21606~7 (a) magnetic particles having loaded thereon a substance that binds to an assay interfering substance in the body fluid through an immunoreaction;
(b) magnetic particles having loaded thereon a substance that binds to the target substance in the body f luid through an immunoreaction; and (c) non-magnetic colored particles having loaded thereon a substance that binds to the target substances in the body fluid through an immunoreaction.
The non-magnetic particles that can be used in the present invention may comprise an organic high-molecular weight substance or an inorganic substance. Exemplary organic high-molecular weight substances include gelatin particles; and latices of organic high-molecular weight substances such as polystyrene and styrene-butadiene copolymer prepared by emulsion polymeri~ation, and use of polystyrene latOE and polyvinyltoluene latex is advantageous. Use of at least one polymer of polystyrene and (meth) acrylate is also possible.
Exemplary (meth) acrylates that can be used include 2-hydroxyethyl (meth) acrylate, 2-hydroxypropyl (meth) acrylate, l-methyl-2-hydroxyethyl (meth) acrylate, glycerol monomethacrylate, 2-acrylamide-2-methylpropanesulfonate, 2-sulfoethyl methacrylate, acid ~h~qph~ncyethyl methacrylate, 3-chloro-2-acid phosphoxyethyl methacrylate, acid phosphu~cyLuLu~,yl methacrylate, ethyl (meth) acrylate, n-butyl (meth) acrylate, i-butyl (meth) acrylate, 2-ethylhexyl (meth) acrylate, lauryl ~ 2160607 methacrylate, cyclohexyl methacrylate, (meth) acrylamide, N-methylol acrylamide, N-buto~methylacrylamide, glycidyl (meth) acrylate, methylglycidyl (meth) acrylate, etc .
Particle size is not limited to any particular range, and may preferably be in the range of from 0.01 to 100 llm, and more preferably, from 0.1 to 30 ~Lm. The particles of such particle size are preferable for i-m-munoreaction since such particles should have sufficient fl~-~t~h;1;ty in an aSIueous solution, and would not precipitate within short period .
The non-magnetic particles are colored by addition of a colorant. The colorant used may pre~erably be the one that would enable mea:,uL. ~ of the absorption at a wave length of from 350 to 1,000 nm.
The magnetic particles used in the present invention are those prepared by incorporating iron or an iron oxide in the above-described particles of an organic high-molecular weight substance or an inorganic substance, or by coating the nucleus oi the above-described particles of an organic high-molecular weight substance or an inorganic substance with a ferrite to thereby produce ferrite-coated particles .
In the present invention, the magnetic particles may be those ~L~U~I~d by further treating the m~nf~t;~
particles that have been prepared as described above with a high-molecular compound. The high-molecular compounds that may be used ~or such treatment include silanes, nylon and polys tyrene .
216~6û7 The particles as described above are loaded with a substance that immunologically binds to the target substance to be assayed or the assay interfering substance in the body fluid. When the target substance or the assay interferir,g substance is a particular antigen, the substance that immunologically binds to such substance is an antibody, and when the target substance or the assay interfering substance is a particular antibody, the substance that immunologically binds to such substance is an antigen.
The procedure for loading the particles with the immunologically binding substance does not differ whether the particles are magnetic or non-magnetic, and an antibody or an antigen is physically adsorbed on the particles or chemically loaded on the particles Physical adsorption may be carried out by reacting said particles with an antigen or an antibody in an ade~auate buffer solution The buffer solutiors that may be used in such reaction include ~h~te buffer saline, Tris-HCl buffer solution, ~rh~ ti~ buffer solution. The reaction will readily proceed when the particles are mixed with the antigen or --the antibody at room temperature, and the desired antigen or antibody-loaded particles will be produced. Chemical loading may be carried out by employing carbodiimide method or glutaraldehyde method used in the so-called peptide binding process.
~ 2160607 g The ~nt;ho~;es loaded on the particles may be either polyclonal or monoclonal, and may be in the form of ~y-globulin, IgG, Ig~q, F(ab' )2, Fab', or the like.
When the substance to be loaded is an antigen, it maybe a cell debris, a hapten, an antigenic protein, an immunocomplex, a natural or synthetic high-molecular weight antigen .
The amount oi the antigen or the antibody loaded on the particles may considerably differ by such factor as the type of the colored particles, and in general, an adequate amount is selected in the range o~ from 0.001 mg/ml to 20 mg/ml, and preferably, from 0.005 mg/ml to 5 mg/ml.
The particles that have been loaded with a substance --that undergoes the immunoreaction are then dispersed in an a~ueous medium such as a buffer solution to 0 . 01 to 10% by weight, and the particles are used as a suspension of latex --particles .
In the assay of the present invention, the particles (a), (b) and (c) as described above are mixed with the body fluid in its step (1).
To 1 volume of non-magnetic colored particles (c) having loaded thereon a substance that immunologically binds to the target substances is used 1/4 to 4 volumes of magnetic particles (b) having loaded thereon a substancè - -that immunologically binds to the target substance; and 1/10 to 10 volumes of magnetic particles (a) having loaded thereon a substance that immunologically binds to an assay , . . .
. ~ 216~607 interfering substance in the body fluid through an immunoreaction .
The particles (a), (b) and ~c) and the body fluid may be mixed in an arbitrary order, and it is possible to mix the magnetic particles (a) and (b) with the non-magnetic particles (c), and then mix the particle mixture with the body fluid; or to mix the non-ma~netic particles (c) with the body fluid, and further with the magnetic particles (a) and (b). It is preferable to mix the magnetic particles (a) and (b) with the non-magnetic particles (c), and then --mix the particle m~xture with the body fluid.
If necessary, the specimen may be diluted with a buf fer or the like .
The mixing procedure is generally carried out at room temperature. However, reaction system may be heated to 30 to 40 C to promote the immunoreaction, or alternatively, cooled to 4 to 20 C for r~-;nt~;n;n~ stability of the reagents .
The step (2) of the assay of the present invention is the step of applying magnetic field to the mixture obtained in step (1).
Intensity of the magnetic ~ield is not limited to any particular range, and typical intensity is in the range o~
1,000 to 10,000 Gauss when the total volume o~ the mixture is 200 ,ul. A commercially available magnetic gatherer such as ~Z~FRTN manufactured by Nippon Paint Co., I;td. may be employed .
. 2~ 6Q~7 In the next step (3), the magnetic particles (a) and (b) that failed to react, and the rnmplP~ c formed by the immunoreaction of the magnetic particles (a) and (b) with particle (c) or with other substance are removed by means of magnetism. The step (3 ) may be cæried out for a non-limited period of time, and typically for 10 seconds to 5 minutes .
In step (4), amount of the colored particles (c) which was not magnetically removed is ~t~rm;n~ by measuring absorption at a wave length of 350 nm or longer, and preferably, from 500 to 700 nm. It is preferable to effect the measurement by using a wave length of the range that is absorbed by the colorant incorporated in the colored particles. The amount of the 1~ ;n;nrJ colored pæticles ( c ) that survived the magnetic removal negatively depends on the content of the target substance in the specimen.
It would be generally preferable to depict a calibration curve by measuring specimens cnnt~;n;n~
different known amounts of the target substance for their absorbance, and concentration of the target substance in the specimen of unknown concentration is determined by referring the calibration curve after measuring the absorbance of the specimen of unknown concentration.
An embodiment of determining the amount of CRP (C-reactive protein) in whole blood is described by ref erring to the drawing. It should be noted that CRP is a ~-globulin in serum whose amount increases in such occasion as ; n f 1 tory diseases accompanying tissue damage .
` ~ 21606~
FIG . 1 shows the case wherein the body f luid assayed is whole blood. As shown in FIG. 1, whole blood contains CRP which is the substance to be assayed together with erythrocytes, hemoglobin, and the like that function as the assay interfering substances. The reagent used for the assay is a mixture of (a) magnetic particles having loaded thereon an anti-human erythrocyte rabbit antibody ~ (a) magnetic particles having loaded thereon a substance that binds to an assay interfering substance in the body fluid through an immunoreaction); (b) magnetic particles having loaded thereon an anti-human CRP goat antibody ( (b) magnetic particles having loaded thereon a substance that binds to the target substance in the body fluid through an inlmunoreaction); and (c) colored particles having loaded thereon an anti-human CRP goat antibody ( (c) non-magnetic colored particles having loaded thereon a substance that binds to the target substances in the body fluid through an ~:
immunoreaction .
When the whole blood is mixed with the reagent, and magnetic field is applied to the mixture, the magnetic particles are collected as shown in the drawing.
The particles collected are particle (a);
immunocomplex of particle (a) with the assay interfering substance; particle (b); the CRP bound to particle (b); and particle (c~ bound to the CRP bound to particle (b). The residual particles that are not magnetically collected are the colored particles (c) having loaded thereon an anti-human CRP goat antibody, which failed to bind to the CRP.
216~607 Shown in FIG. 2 is a schematic calibration curve depicted for blood of known CRP concentrations by measuring the ~h~nrh~n~-e at a wave length of 570 nm. Since the specimen like blood can be assayed with no pretreatment such as adjustment of the blood components by such means as serum separation, an ~- c~ r~t.o~l assay advantageous for such occasions as bedside assay and emergency assay is realized. Capability of the use of the as-collected whole blood for the specimen is particularly advantageous for case o~ the bedside assay.
The assay of the present invention is an immunoassay utilizing magnetic particles. The assay of the present invention, however, may be modified as an EIA, luminescence assay, or the like .
E~MPI.ES
The present invention is hereinaf ter described by referring to the Examples, which by no means limit the scope of the invention.
( Example l ) [Preparation of reagent]
Prep~ration of ~nt;-C'RP; -h;1;7e~1 ~nlnrP~ rtic1e~ (c) Colored particles of 0.2 ~n (colored particles of a styrene polymer prepared by suspension polymerization) was dispersed in l ml of 20~M phosphate buffer saline, pX 7.4 to a solid content of l96.
To the dispersion was then added 0.25 mg of anti-human CRP goat antibody, and the dispersion was stirred. The particles were; -h;1;7ed by storing the dispersion in a refrigerator for 5 days. The dispersion was subjected to centrifugation (12,000 rpr~ x 20 min) to remove the supernatant, and the thus separated colored particles were r~ cp~nfl~o~l in 20rM phosphate buffer saline, pH 7.4 containing 1 ml 19~ bovine serum albumin. The procedure was repeated three tir,es.
Prf~n~rat,i~n Qf ~nti-~'~P; -h; 1; ~ed r~rnptic Particles (b) Ma~netic particles of 2 llm (prepared by styrene polymer particles prepared bY suspension polymerization with ferrite coating) was dispersed in 1 r;L of 20rM
phosphate buffer saline, pH 7.4 to a solid content of 196.
To the dispersion was then added 0 . 25 mg of anti-human CRP
goat antibody, and the dispersion was stirred. The particles were; ~h; l; 7efl by storing the dispersion in a refrigerator for 3 days. The dispersion Was treated in a magnetic separator to remove the supernatant, and the thus separated magnetic particles were res~cpPnfl~d in 20~rM
phosphate buffer saline, pH 7.4 c~nt~;n;n~ 1 ml 19~i bovine ~~
serum albumin. The procedure was repeatea three tLmes.
Pr~on;~rat;on of ~nt;-h~ n ~rvthrocyte ;~ h;1;7ed rr~rnetic ~articl~c (al Magnetic particles of 2 llm (which are similar to the above-described particles) was dispersed in 1 ml of 20mM
phosphate buffer saline, pH 7.4 to a solid content of 1~.
To the dispersion was then added 0 . 25 mg of anti-hur,an 21606~7 erythrocyte rabbit antibody, and the dispersion was stirred. The particles were; h; l; 7ed by storing the dispersion in a refrigerator for 3 days. The dispersion was treated in a magnetic separator to remove the supernatant, and the thus separated magnetic particles were resuspended in 20rn~ phosphate buffer saline, pH 7.4 ~ nt;~;n;n~ 1 ml lS6 bovine serum alburnin. The procedure was repeated three times.
[Selection of the wave length employed for measurement]
The wave length absorbed by the colored particles was ~3f'tP~ by scanning the wave length. The wave length used f or the measurement was the one absorbed by the colorant of the colored particles.
[ Procedure ]
1. Colored particles (c) ; ~h; 1; 7~1 with anti-CRP, magnetic particles (b) immobilized with anti-CRP, and magnetic particles (a) ' h; l ;7ed with anti-human erythrocyte were mixed at a ratio of 1:2:1, and the mixture - --was used for the particle preparation.
2. Standard CRP (25.3 mg~dl) was diluted to different concentrations, and the dilutions were respectively mixed with blood. The mixture was used for :
the specimen.
3. 1 1ll of the specimen and 200 111 of the reagent prepared from the particles were dispensed in the wells of 96 well microplate, and the mixture was stirred, and allowed to react for 5 minutes at room temperature.
4. A magnetic particle-gathering apparatus (GATHERIN, manufactured by Nippon Paint Co., ~td. ) was combined with the microplate, and the immunocomplex of the magnetic particle (b) and the colored particle (c) bound to each other with the intervening CRP antigen; the immunocomplex of the magnetic particles (a) bound to each other with the intervening erythrocyte; and the magnetic particles (a) and (b) that failed to react were magnetically collected.
216~607 In the process of the invention, the magnetic particles may preferably comprise at least one polymer selected from polystyrenes or (meth)acrylates, and have a coating layer of an iron oxide ferrite on its surface. The magnetic particles may have a diameter of from 0 1 to 5 llm, and preferably, 0 . 2 to 3 llm.
In addition, it is preferable that the body fluid is whole blood and the assay interfering substance is erythrocyte; the colored particles are colored particles of one or more types having a diameter of from 0 1 to 5 llm and having at least one color selected from white, black, red, blue, yellow and a color formed by mixing such colors; and the wave length used for measuring the absorbance is in the range of from 350 to 1000 nm.
BRIEF DESCRIPTION OF THE DRAWINGS
[FIG. 1] This figure is a schematic view for explaining the process of the invention [FIG. 2] This figure i5 a schematic view showing an example of the calibration curve used for the present invention n~Tr,r n DESCRIPTION OF THE lNVl ;N'l'lON
The target substance to be assayed by the process o~ `
the present invention is a biological substance found in human or an animal, and the specimen to be evaluated is a body fluid such as blood or urine rf~nt;~;n;nS such a subs tance A body fluid may contain biological substances such as erythrocytes, hemoglobin, bilirubin, and the like as well as drugs such as phenobarbital, phenytoin, digoxin, imipramine, theophylline, penicillin, and the like, and such a subs tance in the specimen to be determined should interfere with the assay to adversely affect the sensitivity and the accuracy of the assay.
The biological substance to be assayed in the present invention is a biological substance that is a particular antigen or antibody present in the body fluid to be assayed. Exemplary such biological substances are as described below.
Antigens: IgG, IgA, IgM, IgE, albumin, HCG, AFP, cardiolipin antigen, blood group substances, concanavalin A, DNT, prostaglandin, CRP, HBs, human growth hormone, steroid hormone, CEA, IgD, ~p(a), Apo-AI, Apo-AII, Apo-CII, Apo-CIII, Apo-B, Apo-E, hemoglobin, etc.
Antibodies: anti-albumin antibodies such as anti-albumin antibody, anti-AFP antibody, etc.; anti-globulin antibodies such as anti-HCG antibody, anti-IgG antibody, anti-IgA antibody, anti-IgM antibody, anti-IgE antibody, anti-IgD antibody, anti-CRP antibody, etc.; anti-hormone antibodies such as anti-human growth horIrlone antibody, anti-steroid antibody, etc.; anti-DNT antibody, anti-prostaglandin antibody, anti-human coagulation factor antibody, anti-HBs antibody, etc.
- In the process of the present invention, particles (a), (b) and (c~ as described below are employed.
21606~7 (a) magnetic particles having loaded thereon a substance that binds to an assay interfering substance in the body fluid through an immunoreaction;
(b) magnetic particles having loaded thereon a substance that binds to the target substance in the body f luid through an immunoreaction; and (c) non-magnetic colored particles having loaded thereon a substance that binds to the target substances in the body fluid through an immunoreaction.
The non-magnetic particles that can be used in the present invention may comprise an organic high-molecular weight substance or an inorganic substance. Exemplary organic high-molecular weight substances include gelatin particles; and latices of organic high-molecular weight substances such as polystyrene and styrene-butadiene copolymer prepared by emulsion polymeri~ation, and use of polystyrene latOE and polyvinyltoluene latex is advantageous. Use of at least one polymer of polystyrene and (meth) acrylate is also possible.
Exemplary (meth) acrylates that can be used include 2-hydroxyethyl (meth) acrylate, 2-hydroxypropyl (meth) acrylate, l-methyl-2-hydroxyethyl (meth) acrylate, glycerol monomethacrylate, 2-acrylamide-2-methylpropanesulfonate, 2-sulfoethyl methacrylate, acid ~h~qph~ncyethyl methacrylate, 3-chloro-2-acid phosphoxyethyl methacrylate, acid phosphu~cyLuLu~,yl methacrylate, ethyl (meth) acrylate, n-butyl (meth) acrylate, i-butyl (meth) acrylate, 2-ethylhexyl (meth) acrylate, lauryl ~ 2160607 methacrylate, cyclohexyl methacrylate, (meth) acrylamide, N-methylol acrylamide, N-buto~methylacrylamide, glycidyl (meth) acrylate, methylglycidyl (meth) acrylate, etc .
Particle size is not limited to any particular range, and may preferably be in the range of from 0.01 to 100 llm, and more preferably, from 0.1 to 30 ~Lm. The particles of such particle size are preferable for i-m-munoreaction since such particles should have sufficient fl~-~t~h;1;ty in an aSIueous solution, and would not precipitate within short period .
The non-magnetic particles are colored by addition of a colorant. The colorant used may pre~erably be the one that would enable mea:,uL. ~ of the absorption at a wave length of from 350 to 1,000 nm.
The magnetic particles used in the present invention are those prepared by incorporating iron or an iron oxide in the above-described particles of an organic high-molecular weight substance or an inorganic substance, or by coating the nucleus oi the above-described particles of an organic high-molecular weight substance or an inorganic substance with a ferrite to thereby produce ferrite-coated particles .
In the present invention, the magnetic particles may be those ~L~U~I~d by further treating the m~nf~t;~
particles that have been prepared as described above with a high-molecular compound. The high-molecular compounds that may be used ~or such treatment include silanes, nylon and polys tyrene .
216~6û7 The particles as described above are loaded with a substance that immunologically binds to the target substance to be assayed or the assay interfering substance in the body fluid. When the target substance or the assay interferir,g substance is a particular antigen, the substance that immunologically binds to such substance is an antibody, and when the target substance or the assay interfering substance is a particular antibody, the substance that immunologically binds to such substance is an antigen.
The procedure for loading the particles with the immunologically binding substance does not differ whether the particles are magnetic or non-magnetic, and an antibody or an antigen is physically adsorbed on the particles or chemically loaded on the particles Physical adsorption may be carried out by reacting said particles with an antigen or an antibody in an ade~auate buffer solution The buffer solutiors that may be used in such reaction include ~h~te buffer saline, Tris-HCl buffer solution, ~rh~ ti~ buffer solution. The reaction will readily proceed when the particles are mixed with the antigen or --the antibody at room temperature, and the desired antigen or antibody-loaded particles will be produced. Chemical loading may be carried out by employing carbodiimide method or glutaraldehyde method used in the so-called peptide binding process.
~ 2160607 g The ~nt;ho~;es loaded on the particles may be either polyclonal or monoclonal, and may be in the form of ~y-globulin, IgG, Ig~q, F(ab' )2, Fab', or the like.
When the substance to be loaded is an antigen, it maybe a cell debris, a hapten, an antigenic protein, an immunocomplex, a natural or synthetic high-molecular weight antigen .
The amount oi the antigen or the antibody loaded on the particles may considerably differ by such factor as the type of the colored particles, and in general, an adequate amount is selected in the range o~ from 0.001 mg/ml to 20 mg/ml, and preferably, from 0.005 mg/ml to 5 mg/ml.
The particles that have been loaded with a substance --that undergoes the immunoreaction are then dispersed in an a~ueous medium such as a buffer solution to 0 . 01 to 10% by weight, and the particles are used as a suspension of latex --particles .
In the assay of the present invention, the particles (a), (b) and (c) as described above are mixed with the body fluid in its step (1).
To 1 volume of non-magnetic colored particles (c) having loaded thereon a substance that immunologically binds to the target substances is used 1/4 to 4 volumes of magnetic particles (b) having loaded thereon a substancè - -that immunologically binds to the target substance; and 1/10 to 10 volumes of magnetic particles (a) having loaded thereon a substance that immunologically binds to an assay , . . .
. ~ 216~607 interfering substance in the body fluid through an immunoreaction .
The particles (a), (b) and ~c) and the body fluid may be mixed in an arbitrary order, and it is possible to mix the magnetic particles (a) and (b) with the non-magnetic particles (c), and then mix the particle mixture with the body fluid; or to mix the non-ma~netic particles (c) with the body fluid, and further with the magnetic particles (a) and (b). It is preferable to mix the magnetic particles (a) and (b) with the non-magnetic particles (c), and then --mix the particle m~xture with the body fluid.
If necessary, the specimen may be diluted with a buf fer or the like .
The mixing procedure is generally carried out at room temperature. However, reaction system may be heated to 30 to 40 C to promote the immunoreaction, or alternatively, cooled to 4 to 20 C for r~-;nt~;n;n~ stability of the reagents .
The step (2) of the assay of the present invention is the step of applying magnetic field to the mixture obtained in step (1).
Intensity of the magnetic ~ield is not limited to any particular range, and typical intensity is in the range o~
1,000 to 10,000 Gauss when the total volume o~ the mixture is 200 ,ul. A commercially available magnetic gatherer such as ~Z~FRTN manufactured by Nippon Paint Co., I;td. may be employed .
. 2~ 6Q~7 In the next step (3), the magnetic particles (a) and (b) that failed to react, and the rnmplP~ c formed by the immunoreaction of the magnetic particles (a) and (b) with particle (c) or with other substance are removed by means of magnetism. The step (3 ) may be cæried out for a non-limited period of time, and typically for 10 seconds to 5 minutes .
In step (4), amount of the colored particles (c) which was not magnetically removed is ~t~rm;n~ by measuring absorption at a wave length of 350 nm or longer, and preferably, from 500 to 700 nm. It is preferable to effect the measurement by using a wave length of the range that is absorbed by the colorant incorporated in the colored particles. The amount of the 1~ ;n;nrJ colored pæticles ( c ) that survived the magnetic removal negatively depends on the content of the target substance in the specimen.
It would be generally preferable to depict a calibration curve by measuring specimens cnnt~;n;n~
different known amounts of the target substance for their absorbance, and concentration of the target substance in the specimen of unknown concentration is determined by referring the calibration curve after measuring the absorbance of the specimen of unknown concentration.
An embodiment of determining the amount of CRP (C-reactive protein) in whole blood is described by ref erring to the drawing. It should be noted that CRP is a ~-globulin in serum whose amount increases in such occasion as ; n f 1 tory diseases accompanying tissue damage .
` ~ 21606~
FIG . 1 shows the case wherein the body f luid assayed is whole blood. As shown in FIG. 1, whole blood contains CRP which is the substance to be assayed together with erythrocytes, hemoglobin, and the like that function as the assay interfering substances. The reagent used for the assay is a mixture of (a) magnetic particles having loaded thereon an anti-human erythrocyte rabbit antibody ~ (a) magnetic particles having loaded thereon a substance that binds to an assay interfering substance in the body fluid through an immunoreaction); (b) magnetic particles having loaded thereon an anti-human CRP goat antibody ( (b) magnetic particles having loaded thereon a substance that binds to the target substance in the body fluid through an inlmunoreaction); and (c) colored particles having loaded thereon an anti-human CRP goat antibody ( (c) non-magnetic colored particles having loaded thereon a substance that binds to the target substances in the body fluid through an ~:
immunoreaction .
When the whole blood is mixed with the reagent, and magnetic field is applied to the mixture, the magnetic particles are collected as shown in the drawing.
The particles collected are particle (a);
immunocomplex of particle (a) with the assay interfering substance; particle (b); the CRP bound to particle (b); and particle (c~ bound to the CRP bound to particle (b). The residual particles that are not magnetically collected are the colored particles (c) having loaded thereon an anti-human CRP goat antibody, which failed to bind to the CRP.
216~607 Shown in FIG. 2 is a schematic calibration curve depicted for blood of known CRP concentrations by measuring the ~h~nrh~n~-e at a wave length of 570 nm. Since the specimen like blood can be assayed with no pretreatment such as adjustment of the blood components by such means as serum separation, an ~- c~ r~t.o~l assay advantageous for such occasions as bedside assay and emergency assay is realized. Capability of the use of the as-collected whole blood for the specimen is particularly advantageous for case o~ the bedside assay.
The assay of the present invention is an immunoassay utilizing magnetic particles. The assay of the present invention, however, may be modified as an EIA, luminescence assay, or the like .
E~MPI.ES
The present invention is hereinaf ter described by referring to the Examples, which by no means limit the scope of the invention.
( Example l ) [Preparation of reagent]
Prep~ration of ~nt;-C'RP; -h;1;7e~1 ~nlnrP~ rtic1e~ (c) Colored particles of 0.2 ~n (colored particles of a styrene polymer prepared by suspension polymerization) was dispersed in l ml of 20~M phosphate buffer saline, pX 7.4 to a solid content of l96.
To the dispersion was then added 0.25 mg of anti-human CRP goat antibody, and the dispersion was stirred. The particles were; -h;1;7ed by storing the dispersion in a refrigerator for 5 days. The dispersion was subjected to centrifugation (12,000 rpr~ x 20 min) to remove the supernatant, and the thus separated colored particles were r~ cp~nfl~o~l in 20rM phosphate buffer saline, pH 7.4 containing 1 ml 19~ bovine serum albumin. The procedure was repeated three tir,es.
Prf~n~rat,i~n Qf ~nti-~'~P; -h; 1; ~ed r~rnptic Particles (b) Ma~netic particles of 2 llm (prepared by styrene polymer particles prepared bY suspension polymerization with ferrite coating) was dispersed in 1 r;L of 20rM
phosphate buffer saline, pH 7.4 to a solid content of 196.
To the dispersion was then added 0 . 25 mg of anti-human CRP
goat antibody, and the dispersion was stirred. The particles were; ~h; l; 7efl by storing the dispersion in a refrigerator for 3 days. The dispersion Was treated in a magnetic separator to remove the supernatant, and the thus separated magnetic particles were res~cpPnfl~d in 20~rM
phosphate buffer saline, pH 7.4 c~nt~;n;n~ 1 ml 19~i bovine ~~
serum albumin. The procedure was repeatea three tLmes.
Pr~on;~rat;on of ~nt;-h~ n ~rvthrocyte ;~ h;1;7ed rr~rnetic ~articl~c (al Magnetic particles of 2 llm (which are similar to the above-described particles) was dispersed in 1 ml of 20mM
phosphate buffer saline, pH 7.4 to a solid content of 1~.
To the dispersion was then added 0 . 25 mg of anti-hur,an 21606~7 erythrocyte rabbit antibody, and the dispersion was stirred. The particles were; h; l; 7ed by storing the dispersion in a refrigerator for 3 days. The dispersion was treated in a magnetic separator to remove the supernatant, and the thus separated magnetic particles were resuspended in 20rn~ phosphate buffer saline, pH 7.4 ~ nt;~;n;n~ 1 ml lS6 bovine serum alburnin. The procedure was repeated three times.
[Selection of the wave length employed for measurement]
The wave length absorbed by the colored particles was ~3f'tP~ by scanning the wave length. The wave length used f or the measurement was the one absorbed by the colorant of the colored particles.
[ Procedure ]
1. Colored particles (c) ; ~h; 1; 7~1 with anti-CRP, magnetic particles (b) immobilized with anti-CRP, and magnetic particles (a) ' h; l ;7ed with anti-human erythrocyte were mixed at a ratio of 1:2:1, and the mixture - --was used for the particle preparation.
2. Standard CRP (25.3 mg~dl) was diluted to different concentrations, and the dilutions were respectively mixed with blood. The mixture was used for :
the specimen.
3. 1 1ll of the specimen and 200 111 of the reagent prepared from the particles were dispensed in the wells of 96 well microplate, and the mixture was stirred, and allowed to react for 5 minutes at room temperature.
4. A magnetic particle-gathering apparatus (GATHERIN, manufactured by Nippon Paint Co., ~td. ) was combined with the microplate, and the immunocomplex of the magnetic particle (b) and the colored particle (c) bound to each other with the intervening CRP antigen; the immunocomplex of the magnetic particles (a) bound to each other with the intervening erythrocyte; and the magnetic particles (a) and (b) that failed to react were magnetically collected.
5. The concentration of the remaining colored particles (c) was ~ .orm;n~d with a microplate reader by measuring absorbance at a wave length of 57 0 nm and a calibration curve was depicted.
(Comparative Example) Pr~nArat;on of Anti-t'RP; h;l;7ed colored ~Articles (c) Colored particles of 0 . 2 llm was dispersed in 1 ml of 20mM phosphate buf~er saline, pX 7.4 to a solid content o~
1~ .
To the dispersion was then added 0.25 mg of anti-human CRP goat antibody, and the dispersion was stirred. The particles were i h; 1; 7ed by storing the dispersion in a refrigerator for 3 days . The dispersion was subj ected to centrifugation (12,000 rpm x 20 min.) to remove the supernatant, and the t~Lus separated colored particles were resl1cpPn~ 1 in 20mM phosphate buffer saline, pH 7.4 ~ , 216060~
c~nt~;n;n~ 1 ml 19~ bovine serum albumin. The procedure was repeated three times.
Pron~ration sf ~nt;-~RP; h;l;7~-1 r~ rn~tlC sarticle5 (b) Magnetic particles of 2 ~lm was dispersed in 1 ml of 20mM phosphate buffer saline, pH 7.4 to a solid content of 196. To the dispersion was then added 0.25 mg of anti-human CRP goat antibody, and the dispersion was stirred. The particles were; h;l;7ed by storing the dispersion in a refrigerator for 3 days. The dispersion was treated in a magnetic separator to remove the supernatant, and the thus separated magnetic particles were resuspended in 20}[M
phosphate buffer saline, pH 7.4 c~Ilt~;n;n~ 1 ml 196 bovine serum albumi~. The procedure was repeated three times.
[Selection of the wave length employed for measurement]
The wave length absorbed by the colored particles was detected by scanning the wave length. The wave length used for the measurement was the one absorbed by the colorant of the colored particles.
[ Procedure]
1. Colored particles (c~ immobilized with anti-CRP
and magnetic particles ~b) immobilized with anti-CRP were mixed at a ratio of 1:2, and the mixture was used for the particle preparation.
2. Standard CRP (25.3 mg/dl) was diluted to different co~centrations, and the dilutions were , ~ , 2160607 respectively mixed with blood. The mixture was used for the ~rP~;
3. 1 111 of the specimen and 200 ,ul of the reagent prepared from the particles were dispensed in the wells of 96 well microplate, and the mixture was stirred, and allowed to react for 5 minutes at room temperature.
4. A magnetic particle-gathering apparatus (r.~ RRT~, manufactured by Nippo~ Paint Co., ~td. ) was combined with the microplate, and the immunocomplex of the magnetic particle (b) and the colored particle (c) bound to each other with the intervening CRP antigen; and the magnetic particles (b) that failed to react were magnetically collected.
5 . The concentration of the ~ ; n; n~ colored particles (c) was detPrrn;nPd with a microplate reader by measuring absorbance at a wave length of 5~0 nm and a calibration curve was depicted.
In Example l, maslnetic particles (a) that had been immobilized with the anti-human erythrocyte antibody were present in the reagent prepared from particles, and therefore, when the blood was used for the specimen, the absorbance decreased with the increase in the antigen c~n~Pnt~Ation to enable assay of the antigen concentration at a high accuracy. On the other hand, no decrease in the absorbance with the increase in the antigen concentration was observed in Comparative Example.
~ 21 6~607 The process of the present invention is an improvement in the; Inn~ ay employing the magnetic and non-magnetic particles. Since the process of the present invention involves the addition of the magnetic particles having loaded thereon a substance that binds to the assay interfering substance in the body fluid to be assayed, an accelerated assay at a high sensitivity with no influence of the assay interfering substance is enabled even when the sample is an untreated body fluid.
(Comparative Example) Pr~nArat;on of Anti-t'RP; h;l;7ed colored ~Articles (c) Colored particles of 0 . 2 llm was dispersed in 1 ml of 20mM phosphate buf~er saline, pX 7.4 to a solid content o~
1~ .
To the dispersion was then added 0.25 mg of anti-human CRP goat antibody, and the dispersion was stirred. The particles were i h; 1; 7ed by storing the dispersion in a refrigerator for 3 days . The dispersion was subj ected to centrifugation (12,000 rpm x 20 min.) to remove the supernatant, and the t~Lus separated colored particles were resl1cpPn~ 1 in 20mM phosphate buffer saline, pH 7.4 ~ , 216060~
c~nt~;n;n~ 1 ml 19~ bovine serum albumin. The procedure was repeated three times.
Pron~ration sf ~nt;-~RP; h;l;7~-1 r~ rn~tlC sarticle5 (b) Magnetic particles of 2 ~lm was dispersed in 1 ml of 20mM phosphate buffer saline, pH 7.4 to a solid content of 196. To the dispersion was then added 0.25 mg of anti-human CRP goat antibody, and the dispersion was stirred. The particles were; h;l;7ed by storing the dispersion in a refrigerator for 3 days. The dispersion was treated in a magnetic separator to remove the supernatant, and the thus separated magnetic particles were resuspended in 20}[M
phosphate buffer saline, pH 7.4 c~Ilt~;n;n~ 1 ml 196 bovine serum albumi~. The procedure was repeated three times.
[Selection of the wave length employed for measurement]
The wave length absorbed by the colored particles was detected by scanning the wave length. The wave length used for the measurement was the one absorbed by the colorant of the colored particles.
[ Procedure]
1. Colored particles (c~ immobilized with anti-CRP
and magnetic particles ~b) immobilized with anti-CRP were mixed at a ratio of 1:2, and the mixture was used for the particle preparation.
2. Standard CRP (25.3 mg/dl) was diluted to different co~centrations, and the dilutions were , ~ , 2160607 respectively mixed with blood. The mixture was used for the ~rP~;
3. 1 111 of the specimen and 200 ,ul of the reagent prepared from the particles were dispensed in the wells of 96 well microplate, and the mixture was stirred, and allowed to react for 5 minutes at room temperature.
4. A magnetic particle-gathering apparatus (r.~ RRT~, manufactured by Nippo~ Paint Co., ~td. ) was combined with the microplate, and the immunocomplex of the magnetic particle (b) and the colored particle (c) bound to each other with the intervening CRP antigen; and the magnetic particles (b) that failed to react were magnetically collected.
5 . The concentration of the ~ ; n; n~ colored particles (c) was detPrrn;nPd with a microplate reader by measuring absorbance at a wave length of 5~0 nm and a calibration curve was depicted.
In Example l, maslnetic particles (a) that had been immobilized with the anti-human erythrocyte antibody were present in the reagent prepared from particles, and therefore, when the blood was used for the specimen, the absorbance decreased with the increase in the antigen c~n~Pnt~Ation to enable assay of the antigen concentration at a high accuracy. On the other hand, no decrease in the absorbance with the increase in the antigen concentration was observed in Comparative Example.
~ 21 6~607 The process of the present invention is an improvement in the; Inn~ ay employing the magnetic and non-magnetic particles. Since the process of the present invention involves the addition of the magnetic particles having loaded thereon a substance that binds to the assay interfering substance in the body fluid to be assayed, an accelerated assay at a high sensitivity with no influence of the assay interfering substance is enabled even when the sample is an untreated body fluid.
Claims (4)
1. A process for assaying a biological substance characterized in that said process comprises the steps (1) to (4) carried out in this order:
(1) the step of mixing a body fluid with particles (a), (b) and (c):
(a) magnetic particles having loaded thereon a substance that binds to an assay interfering substance in the body fluid through an immunoreaction;
(b) magnetic particles having loaded thereon a substance that binds to the target substance in the body fluid through an immunoreaction; and (c) non-magnetic colored particles having loaded thereon a substance that binds to the target substances in the body fluid through an immunoreaction;
(2) the step of applying magnetic field to the mixture;
(3) the step of removing the complexes formed by the immunoreaction of the magnetic particles and the magnetic particles that failed to react by means of magnetism; and (4) the step of determining the amount of the remaining colored particles by measuring their absorption at a wave length of 350 nm or longer to thereby qualify or quantify the target substance in the body fluid without being influenced by the interfering substances in the body fluid.
(1) the step of mixing a body fluid with particles (a), (b) and (c):
(a) magnetic particles having loaded thereon a substance that binds to an assay interfering substance in the body fluid through an immunoreaction;
(b) magnetic particles having loaded thereon a substance that binds to the target substance in the body fluid through an immunoreaction; and (c) non-magnetic colored particles having loaded thereon a substance that binds to the target substances in the body fluid through an immunoreaction;
(2) the step of applying magnetic field to the mixture;
(3) the step of removing the complexes formed by the immunoreaction of the magnetic particles and the magnetic particles that failed to react by means of magnetism; and (4) the step of determining the amount of the remaining colored particles by measuring their absorption at a wave length of 350 nm or longer to thereby qualify or quantify the target substance in the body fluid without being influenced by the interfering substances in the body fluid.
2. A process for assaying a biological substance according to claim 1 wherein said magnetic particles are particles comprising at least one polymer selected from polystyrenes and (meth) acrylates having a coating layer of an iron oxide ferrite on its surface, and said particles have a diameter of from 0.2 to 3 µm.
3. A process for assaying a biological substance according to claim 1 or 2 wherein said body fluid is whole blood, and said an assay interfering substances is erythrocyte, leukocyte, platelet, hemoglobin, bilirubin, or a lipoprotein.
4. A process for assaying a biological substance according to any one of claims 1 to 3 wherein said colored particles are colored particles having a diameter of from 0.1 to 5 µm and having at least one color selected from white, black, red, blue, yellow and colors formed by mixing such colors; and the wave length used for measuring the absorbance is in the range of from 350 to 1000 nm.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002160607A CA2160607A1 (en) | 1995-10-16 | 1995-10-16 | Assay method for analyte in living body |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002160607A CA2160607A1 (en) | 1995-10-16 | 1995-10-16 | Assay method for analyte in living body |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2160607A1 true CA2160607A1 (en) | 1997-04-17 |
Family
ID=4156773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002160607A Abandoned CA2160607A1 (en) | 1995-10-16 | 1995-10-16 | Assay method for analyte in living body |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2160607A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018060447A1 (en) * | 2016-09-30 | 2018-04-05 | Biopromic Ab | Method for removing inhibitory components |
-
1995
- 1995-10-16 CA CA002160607A patent/CA2160607A1/en not_active Abandoned
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018060447A1 (en) * | 2016-09-30 | 2018-04-05 | Biopromic Ab | Method for removing inhibitory components |
| CN109791148A (en) * | 2016-09-30 | 2019-05-21 | 普洛米生科有限公司 | Method for removing inhibition component |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU695012B2 (en) | Immunoassay for determination of cells | |
| US5145784A (en) | Double capture assay method employing a capillary flow device | |
| US5998224A (en) | Magnetically assisted binding assays utilizing a magnetically responsive reagent | |
| US5460979A (en) | Indirect fluorescent assay of blood samples | |
| US6294342B1 (en) | Magnetically assisted binding assays utilizing a magnetically responsive reagent | |
| EP1532448B1 (en) | Self-calibration system for a magnetic binding assay | |
| EP0724156A1 (en) | Kit for immunologically assaying biological substance and assay process | |
| EP2146207A1 (en) | Measurement reagent, immune nephelometry using the same, and analyte analysis tool | |
| US5583054A (en) | Determination and detection of antibody and its immunoglobulin class | |
| WO1995015498A1 (en) | Immunoassays employing generic anti-hapten antibodies and materials for use therein | |
| EP0768530A1 (en) | Process for assaying biological substance | |
| GB2045431A (en) | Immunoassay utilising two particulate reagents | |
| MXPA05001681A (en) | Flow-through assay with an internal calibration system using___magnetic particles. | |
| WO2002039114A2 (en) | Improved assay and reagents or immunological determination of analyte concentration | |
| US5270166A (en) | Immunoassays employing generic anti-hapten antibodies and materials for use therein | |
| JPH08262024A (en) | Kit for immunoassay of in vivo substance and immunoassay method | |
| EP0357786B1 (en) | Method for assaying antigen or antibody | |
| US5202269A (en) | Method for immunochemical determination of hapten | |
| CA2160607A1 (en) | Assay method for analyte in living body | |
| JPH07151759A (en) | Reagent for acquiring reactant, intermediate thereof and acquiring method | |
| US10509028B2 (en) | Use of a low-density immiscible compound in a device for detecting an analyte in a sample | |
| JPH0862214A (en) | Method for measuring substance in vivo | |
| JPH0468588B2 (en) | ||
| JP2024084754A (en) | Lateral flow assays and methods for detecting high concentrations of analytes - Patents.com | |
| Nustad et al. | Monosized polymer particles in immunoassays. Applications and immunochemistry |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 19981016 |